Comparison between Avience Biomedicals IPO and Galaxy Medicare IPO.
Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Galaxy Medicare IPO is a SME Bookbuilding proposed to list at NSE SME.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. | Affinity Global Capital Market Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | Cameo Corporate Services Ltd. |
| Market Maker | Asnani Stock Broker Pvt.Ltd. | Prabhat Financial Services Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Avience Biomedicals IPO is up to ₹28.53 Cr whereas the issue size of the Galaxy Medicare IPO is up to ₹21.19 Cr. The final issue price of Avience Biomedicals IPO is ₹208.00 per share and of Galaxy Medicare IPO is ₹54.00 per share.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹196.00 per share | ₹51.00 per share |
| Issue Price (Upper) | ₹208.00 per share | ₹54.00 per share |
| Issue Price (Final) | ₹208.00 per share | ₹54.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 600 shares | 2000 shares |
| Fresh Issue Size | 13,71,600 shares | 31,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹28.53 Cr | up to ₹16.74 Cr |
| OFS Issue Size | 0 shares | 8,24,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹4.45 Cr |
| Issue Size Total | 13,71,600 shares | 39,24,000 shares |
| Issue Size Total (Amount) | up to ₹28.53 Cr | up to ₹21.19 Cr |
Avience Biomedicals IPO opens on Jun 18, 2026, while Galaxy Medicare IPO opens on Sep 10, 2025. The closing date of Avience Biomedicals IPO and Galaxy Medicare IPO is Jun 22, 2026, and Sep 12, 2025, respectively.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Anchor Bid Date | Jun 17, 2026 | |
| Issue Open | Jun 18, 2026 | Sep 10, 2025 |
| Issue Close | Jun 22, 2026 | Sep 12, 2025 |
| Basis Of Allotment (Tentative) | Jun 23, 2026 | Sep 15, 2025 |
| Initiation of Refunds (Tentative) | Jun 24, 2026 | Sep 16, 2025 |
| Credit of Share (Tentative) | Jun 24, 2026 | Sep 16, 2025 |
| Listing date (Tentative) | Jun 25, 2026 | Sep 17, 2025 |
| Anchor Lockin End date 1 | Jul 23, 2026 | |
| Anchor Lockin End date 2 | Sep 21, 2026 |
Avience Biomedicals IPO P/E ratio is 11.59, as compared to Galaxy Medicare IPO P/E ratio of 19.01.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 87.89 | 99.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 64.59 | 72.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.59 | 19.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹114.09 Cr. | ₹81.93 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.14 | 19.88 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.84 | 22.38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.97 | 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹17.94 | ₹2.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 49.89 | 18.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 4,81,200 shares while in Galaxy Medicare IPO retail investors are offered 4,81,200 shares. Qualified Institutional Buyers (QIB) are offered 2,73,600 shares in Avience Biomedicals IPO and 80,000 shares in Galaxy Medicare IPO.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Anchor Investor Reservation | 4,09,800 shares | 0 shares |
| Market Maker Reservation | 82,200 shares | 2,08,000 shares |
| QIB | 2,73,600 shares | 80,000 shares |
| NII | 2,07,000 shares | 15,36,000 shares |
| RII | 4,81,200 shares | 23,08,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 13,71,600 shares | 39,24,000 shares |
Avience Biomedicals IPO subscribed 270.19x in total, whereas Galaxy Medicare IPO subscribed 1.83x.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| QIB (times) | 196.77x | 1.00x |
| NII (times) | 597.23x | 1.48x |
| Big NII (times) | 670.18x | 1.88x |
| Small NII (times) | 451.35x | 0.66x |
| RII (times) | 401.36x | 2.10x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 270.19x | 1.83x |
